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PENILAIAN KEBOLEHTELAPAN MITRAGININA MENGGUNAKAN 
USUS TIKUS IN SITU 
ABSTRAK 
Alkaloid utama dalam daun M. speciosa, mitraginina adalah 
bertanggungjawab terhadap kebanyakan kesan farmakologi yang telah dilaporkan. 
Dalam kajian yang telah dijalankan ke atas mikrosom hati, alkaloid ini didapati 
stabil. Walau bagaimanapun, bioketersediaan mitraginina telah dilaporkan sangat 
rendah. Kadar penyerapan oral mitraginina yang rendah ini mungkin disebabkan oleh 
sifat keterlarutan air yang rendah. Di samping itu, kebolehtelapan usus, enzim 
sitokrom P450 3A4 (CYP3A4), dan sistem eflux p-glikoprotein (P-gp) berperanan 
penting dalam bioketersediaan oral mitraginina. Oleh yang demikian, penyelidikan 
ini telah dijalankan untuk menentukan beberapa ciri penyerapan oral dengan 
menggunakan model perfusat usus tikus in situ. Satu kaedah HPLC-UV yang baru 
telah dibangunkan untuk pengesanan serentak mitraginina, propranolol dan atenolol 
untuk kuantifikasi mitraginina dalam sampel perfusat usus tikus in situ. LOQ bagi 
mitraginina, propranolol dan atenolol adalah masing-masing 2.5, 3.75 dan 3.75 
μg/mL. Kejituan dan ketelitian kaedah HPLC-UV bagi mitraginina, propranolol dan 
atenolol masing-masing adalah di bawah 5%. Mitraginina telah didapati stabil dalam 
asetonitril dan penimbal perfusat pada suhu -20
o
C selama satu bulan. Kestabilan juga 
tidak terjejas apabila sampel terdedah di meja makmal selama 8 jam dan selepas tiga 
kitaran beku dan cair. Keterlarutan mitraginina dalam penimbal perfusat adalah 
kurang baik (~40μg/mL). Mitraginina menunjukkan kebolehtelapan yang tinggi 
dalam usus (Peff) (1.11 x 10-4 cm / s), iaitu setanding dengan penanda kebolehtelapan 
tinggi propranolol (Peff) (1.27 x 10-4 cm / s). Tidak ada perubahan yang signifikan 
xx 
 
(p>0.05) dalam nilai min kebolehtelapan (Peff) mitraginina apabila ia diberi bersama 
perencat P-gp dan/atau CYP3A4. Oleh itu, mitraginina mungkin tidak tertakluk 
kepada penyingkiran pra-sistemik yang berkaitan dengan P-gp dan enzim CYP3A4.  
Kajian ini menunjukkan bahawa mitraginina (kelarutan rendah & kebolehtelapan 
yang tinggi) boleh diklasifikasikan sebagai drug kelas II mengikut sistem klasifikasi 
biofarmaseutikal (BCS). Sifat penyerapan oral mitraginina yang telah didapati dalam 
kajian ini boleh membantu untuk memberikan penyerapan yang mencukupi untuk 
mewujudkan formulasi oral mitraginina bagi kajian klinikal pada masa depan. 
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EVALUATION OF RAT IN SITU INTESTINAL PERMEABILITY STUDY 
OF MITRAGYNINE 
ABSTRACT 
Mitragynine the principal alkaloid of M. speciosa leaf has been reported to be 
responsible for most of its pharmacological effects. Mitragynine has been found to be 
metabolically stable in liver microsomes. However the oral bioavailability of 
mitragynine has been reported to be very low. The poor mitragynine oral absorption 
was due but not limited to, its poor water solubility. It is also important to note that 
the role of intestinal permeability, cytochrome P450 3A4 enzyme (CYP3A4) and p-
glycoprotein (P-gp) efflux system on its oral bioavailability could not be ruled out as 
well. In view of this, work was undertaken to determine some of its oral absorption 
properties using in situ rat intestinal perfusate model in rats. For mitragynine 
quantification in in situ rat intestinal perfusate samples, a reliable HPLC-UV 
analytical method for simultaneous detection of mitragynine, propranolol and 
atenolol was developed and validated. The LOQ of mitragynine, propranolol and 
atenolol were 2.5, 3.75 and 3.75 µg/mL respectively. The within day and day to day 
accuracy and precision for mitragynine, propranolol and atenolol were all below 5% 
respectively. Mitragynine is stable in acetonitrile for period of one month when 
stored in freezer (-20
o
C). All the analytes have been found to be stable in perfusion 
buffer upon storage at -20 °C up to one month. The stability was not affected after 
the samples were subjected to three freeze and thaw cycles and when kept on the 
bench for 8 hours. Mitragynine is poorly soluble in perfusate buffer (~40µg/mL). 
Mitragynine demonstrated high intestinal permeability (Peff) (1.11 x 10
-4 
cm/s) and 
was comparable to that of the high permeable marker propranolol (Peff) (1.27 x 10
-4 
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cm/s). There was no significant alteration (p > 0.05) in the mean permeability values 
(Peff) of mitragynine when P-gp and/or CYP3A4 inhibitors were co-administered, 
thus suggesting the drug is not subjected to pre-systemic elimination related to a P-gp 
and CYP3A4 system. This study suggests that mitragynine (low solubility & high 
permeability) can be classified as class II drug according to biopharmaceutical 
classification system (BCS). The mitragynine oral absorption properties determined 
in this study could further assist the development of mitragynine oral formulation 
which would provide adequate absorption for clinical investigations in the future.
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CHAPTER 1  
INTRODUCTION 
 
 For millennia, when it comes to providing medically useful compounds for 
Mankind’s needs, the Plant kingdom has been the oldest source, offering 
pharmacologically active substances (Cordell, 1981). Plants have been used by the 
human beings over thousands of years for the treatment of various diseases 
(Sofowara, 1982; Hill, 1989). Reports from World Health Organization, suggest that 
most people in many part of the world still rely on conventional medicines for their 
health benefit necessities. Rural communities worldwide still seek the need of 
conventional medicines and have become an integral part of their primary health care 
(Rabe & Van Staden, 2000). Traditional medicines are easily accessible and much 
cheaper when compared with synthetic or modern medicine (Iwu et al., 1999; Mann 
et al., 2008). Some people from their personal experience understand that a 
traditional remedy is valuable in maintaining human health. They know that some 
medicinal plants are highly effective when used at therapeutic doses without 
knowing the science behind these medicines (Maheshwari et al., 1986; Van Wyk et 
al., 2000). Research on many mainstream medicines has revealed that these 
medicines contain numerous compounds which have been derived from 
“ethnomedical” plant sources (Fabricant & Farnsworth, 2001). 
 Increasing demand on herbal medicines in developed and developing 
countries explain that it act as a source of primary health care owing to their 
medicinal property, high safety margins and lesser operational costs when dealing 
with them. This includes Malaysia, which is rich with a diverse quantity of medicinal 
plants. However, most of these medicinal plants have not been extensively exploited 
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or investigated (Jamal, 2006). Among the promising medicinal plants, Mitragyna 
speciosa Korth (M. speciosa) should be given more attention for its valuable 
medicinal properties and its traditional usage in treating various diseases. 
 Mitragyna speciosa Korth belongs to the family Rubiaceae and it is found in 
the tropical and sub-tropical regions of Asia. This tropical plant is known as “Biak- 
Biak” in Malaysia and as “kratom” in Thailand. Red vein and green vein are the two 
types of kratom found in Thailand. Stronger biological activities have been observed 
in red vein variety when compared with the green vein (Chittrakarn et al., 2008). 
Traditionally ketum has been used as a substitute for opium in Thailand and 
Malaysia. Ketum leaves are consumed fresh or make as dried leaf powder which is 
either swallowed or prepared as tea (Chittrakarn et al., 2008). Ketum has been the 
traditional cure for the bacterial related stomach ailments such as diarrhea (Hassan et 
al., 2013). In Malaysia, it is consumed both in adulterated and unadulterated form by 
mixing it with cough mixtures, traditional herbs and even synthetic pyrethroid from 
mosquito coils to add zest to the concoction. The adulterated decoction of M. 
speciosa leaves, known locally as “Ketum juice” is packed into plastic bottles or 
packets and is found being sold in the streets of Peninsular Malaysia, particularly in 
the Northern region. In this region “ketum juice” is consumed by addicts as a 
substitute for the more expensive opiates in order to manage withdrawal symptoms.  
Ketum has been reported to be a central nervous system stimulant rather than 
a depressant. It also enhances work efficiency and tolerance to hard work under the 
heat of the sun (Suwanlert, 1975). In addition to this, Burkill and Haniff (1930) 
documented other uses of ketum, being for the healing of wounds and as a cure for 
fever. Based on what has been mentioned about M. speciosa, it is opined that this 
plant warrants a more extensive investigation of its pharmacological properties. M. 
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speciosa has been under investigation since 1986 in Malaysia. Thailand, Myanmar, 
Malaysia, Vietnam and Australia are among the countries which declared ketum 
usage is illegal. However, free accessibility and information on ketum is widely 
available over the internet. This has fascinated many Westerners to exploit the plant 
as self-treatment in opioid withdrawal and pain management (Boyer, 2007).   
Among the 25 alkaloids, mitragynine is the major alkaloid isolated from 
ketum leaves. In 1907, the isolation of mitragynine first performed by David Hooper 
followed by E. J. Field in 1921. The name “mitragynine” was given by E. J. Field.     
Mitragynine has an antinociceptive effect through an action on supraspinal opioid 
receptors and descending noradrenergic and serotonergic systems (Matsumoto et al., 
2005b).  
Since mitragynine is the major alkaloid derived from ketum leaves which 
have many medicinal values, it is important to conduct a study on its oral 
bioavailability. Oral bioavailability of a drug is the determination of the fraction of a 
drug that reaches the blood stream when it administrated orally. Parthasarthy et al 
(2010) reported a poor oral bioavailability for MG in rats (3%). In most recent 
studies, MG was reported for its poor water solubility (< 100µg/mL) and found to be 
acid degradable. MG is both hydrophobic and lipophilic in nature. MG poor 
bioavailability was constantly attributed to the drug’s sub-optimal physicochemical 
properties (Ramanathan et al 2015). MG is metabolically stable in both human liver 
microsomes and S9 fractions (Manda et al., 2014).  
1.1 Problem statement 
It is of important to note that the role of CYP3A4, P-gp efflux system and 
MG intestinal permeability in effecting drug oral bioavailability could not be ruled 
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out. As off to date there are no studies reported on MG intestinal permeability and its 
pre-systemic drug elimination. In view of this, work was undertaken to determine 
MG intestinal permeability coefficient using a validated rat intestinal in situ perfusate 
model. MG permeability was also investigated in the presence of P-gp efflux system   
and CYP3A4 inhibitors.  
1.2 Expected outcome 
With the data obtained from solubility and permeability experiments carried 
out in this thesis, MG can be classified in accordance with Biopharmaceutical 
Classification System (BSC).  
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1.3 Objectives 
 To develop and validate an HPLC method for simultaneous determination of 
mitragynine, atenolol and propranolol in intestinal rat perfusate. 
 To determine stability of mitragynine in intestinal rat perfusate. 
 To determine the mitragynine permeability using in situ intestinal rat 
perfusion model. 
 To determine the mitragynine permeability using in situ intestinal rat 
perfusion model in the presence of p-glycoprotein inhibitor and/or 
cytochrome P450 A3 inhibitor. 
 
The research scheme is presented in figure 1.1. 
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Evaluation of rat in situ intestinal permeability study of 
mitragynine 
HPLC method development and validation for the simultaneous 
detection of mitragynine, atenolol and propranolol in perfusion buffer 
Mitragynine stability, solubility 
and adsorption studies 
In situ single pass rat intestinal 
permeability study (SPIP) 
Mitragynine stability in 
organic solvent (ACN) at 
– 20 °C 
Mitragynine solubility in 
perfusion buffer 
Mitragynine, atenolol and 
propranolol stability in perfusion 
buffer on bench, freeze thaw and 
short-term stability 
Mitragynine non-specific 
adsorption study 
SPIP of mitragynine in 
the presence of 
permeability markers 
SPIP of mitragynine in 
the presence of P-gp 
inhibitor 
 
SPIP of mitragynine in 
the presence of CYP3A4 
inhibitor 
 
SPIP of mitragynine in the 
presence of both CYP3A4 and 
P-gp inhibitors 
 Figure 1.1 Flow chart of the 
study 
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 CHAPTER 2  
LITERATURE REVIEW 
 
2.1 The role of plants as sources of herbal medicine 
 Plants have been used for health and medical purposes since ancient times. 
The number of higher plant species on earth is about 250 000. It is estimated that in 
some cultures, 35 000 to 70 000 species have, at one time or another, been used for 
medicinal purposes (WHO, 1998). Silano et al. (2004) reported that herbal 
substances composed of one or more bioactive substances are regarded as herbal 
medicines. These herbal substances may be present in whole plant or particular parts 
of the plant such as the root, stem, leaf, flower, fruit and bark of the plant.   
Herbal medicines still has been the first-line of treatment for the majority of 
population around the globe. This is because herbal medicines are main accessible 
and reasonable treatment for the poor people and people living in the rural areas. 
Besides that, people also prefer herbal medicines due to high cost of modern 
treatments, lack of drug supply, side effects and resistance development nature of 
several allopathic drugs. 
Automated separation techniques, high-throughput screening, combinatorial 
chemistry and biological activity guided isolation techniques are the important 
elements in drug discovery derived from natural product. There are many examples 
of new drugs derived from plant-based products such as morphine and digoxin. 
Poppy plant (Papaver somniferum) is the main producer of opium and morphine is 
isolated from it. Digitalis lanata is a flower that produces digoxin which is a heart 
stimulant. Aspirin, quinine, and pilocarpine are also of plant origin, which laid the 
basis for early medicine. Additionally there are several antibiotics for example 
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tetracycline, erythromycin, antimalarial drug (artemisinin) and anticancer drugs 
(paclitaxel and irinotecan) are derivates of plant origin or semi-synthetic derivates 
(Katiyar et al., 2012; Harvey, 2008). 
Medicinal plants play a major role in the drug discovery because they have 
more extensive structural diversity than synthetic drug because their chemical 
derivatives are of organic or natural origin (eg: plant). Thus medicinal plants were 
used widely in pharmaceutical drug discovery due to their varied pharmacological or 
biological properties. Natural products are difficult to synthesize and their production 
cost is high because their structure is more complex with more bridgehead 
tetrahedral carbon atoms, rings, and chiral (Koehn & Carter, 2005). 
The biodiversity of natural products in Malaysia is enormous. Nevertheless, 
major drawback could be attributed to the lack of utilization of natural resources as 
an avenue for new drugs. Research on the pharmacological properties of these 
natural products is limited and lacks sound scientific finding. A few examples of 
Malaysian plants which yield medicinal drugs are the pennywort (pegaga), 
andrographis paniculata (hempedu bumi), devil’s trumpet (kecubung), the pinang 
palm (pokok pinang), the castor oil plant (pokok jarak) and ‘pokok cerita’ (Jamal, 
2006). A local plant M. speciosa has psychotropic characteristics; it was customarily 
used to lessen pain, blood pressure, cough, intestinal disorders and also used as an 
alternative to morphine in treating drug abuse patients (Khor et al., 2011; Chan et al., 
2005). M. speciosa therefore is considered a psychostimulant and need for research 
to ascertain these claims is essential. It has gained recognition nationally and 
internationally because of it various medicinal values. 
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2.2 Mitragyna speciosa 
2.2.1 General description of the plant 
 Mitragyna speciosa Korth. belongs to the family of Rubiaceae (coffee 
family), it is a evergreen tree found in tropical and sub-tropical regions of South East 
Asia and Africa. Asian M. speciosa are often found in rainforests, while the African 
species are often found in swamps. M. speciosa is also called as Ketum, Kakuam, 
Ithang and Thom in different South-East Asian regions and locations (Devotee, 
2009). Genus of this plant ‘Korth’ was named after Pieter William Korthal, a botanist 
who first found the stigma of its flower resembling a bishop’s mitre (Shellard, 1974). 
 
Taxonomy of Mitragyna speciosa Korth. 
Kingdom: Plantae 
Division: Magnoliophyta 
Class: Magnoliopsida 
Order: Gentianales 
Family: Rubiaceae 
Subfamily: Cinchonoideae 
Tribe: Naucleeae 
Genus: Mitragyna  
Species: Mitragyna speciosa 
 
2.2.2 Botanical description of the plant 
M. speciosa trees have an average height of 4-9 m and 5 m wide. Whereas, 
few trees can reach heights up to 15-30 m (Shellard, 1974). The stems are erect and 
branching and could grow over 18 cm long and 10 cm wide with an ovateacuminate 
shape and tapered ends (Hassan et al., 2013). Deep yellow flowers of the M. speciosa 
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grow in globular clusters each containing up to 120 florets (Fig. 2.1). During the 
flower’s bud stage, each developing floret will be surrounded and fully cover by 
many overlapping bracteoles. Dichasial cyme is the inflorescence of M. speciosa 
(Shellard, 1974). The fruits of M. speciosa look like a capsule which containing 
many small flat seeds (Shellard & Lees, 1965; Emboden, 1979). The leaves are dark 
glossy green in color (Fig. 2.1). The young woody shoots bear up to 10-12 leaves 
arranged in opposite and decussate pairs. Two interpetiolar stipules can be seen 
together with a pair of leaves where they are closely appressed and protect the apical 
bud (Shellard, 1974).  
The leaves are always being shed and replaced, however there is some semi 
regular leaf shedding because of ecological conditions. Amid the dry season the 
leaves fall widely and new development is created amid the rainy season (Hassan et 
al., 2013). The ideal development state of the M. speciosa is wet, sticky, rich soil, 
with medium to full sun exposure in zones shielded from firm winds (Macko, 1972; 
Hassan et al., 2013). 
  There are 2 types of M. speciosa plant. One has a leaves with a red petiole 
while the other with a white-greenish petiole. The petiole is the stalk attaching the 
leaf blade to the stem. For the pharmacological studies, MG was isolated from the 
red petiole type of M. speciosa leaves. 
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Figure 2.1: Mitragyna speciosa flower and leaves 
 
2.2.3 Traditional use of Mitragyna speciosa 
M. speciosa has been traditionally used in Thailand and Malaysia as a 
substitute for opium when opium is unavailable, or to moderate opium addiction. 
Ketum has been used to prolong sexual intercourse by small number of people in 
rural areas. Generally, peasants, workers and farmers are among the people who 
consume ketum to overcome the burdens of their hard work (Reanmongkol et al., 
2007). With time, some users find that they need to increase doses to 10-30 leaves or 
even more per day (Anon, 2006). Traditionally, ketum has been utilized as a leaf 
poultice to treat fever and wound healing (Burkill, 1935). In the northern region of 
Peninsular Malaysia, adulterated decoction of M. speciosa leaves are packed in 
plastic bottles or packets and sold as “ketum juice” in the streets. In this region, 
“ketum juice” is consumed by addicts as a substitute for more expensive opiates to 
manage withdrawal symptoms.  
In Malaysia and Thailand, M. speciosa was observed to be utilized as an 
opium substitution as a part of the treatment of opium addiction in the early years 
(Beckett et al, 1965; Tanguay, 2011). Nevertheless, a study led in 1975 uncovered 
that ketum consumers in Thailand were slowly dependent on it (Suwanlert, 1975). 
Hence, discoveries reported that there has been a generous development among the 
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Malaysian drug addicts who utilize the ketum leaves to wean themselves off from 
narcotic withdrawal indications (Vicknasingam et al., 2010). In any case, long haul 
ketum utilization can prompt its misuse simply like different drugs, for example, 
cannabis and heroin. This phenomenon caused extensive worry among general 
society and law enforcement authorities where it can create new addiction among the 
young generation (Ahmad & Aziz, 2012). At present, the ketum utilization in 
overseeing compulsion and withdrawal side effects is happening in an unsupervised, 
casual, scattered and unrecorded way. Therefore, the danger of serious dependence 
on ketum in an uncontrolled manner hinders its genuine potential as a simple home 
remedy that exhibits effective in any medication substitution program. 
 
2.2.4 Pharmacological activities of Mitragyna speciosa 
In 1836, native Malayans used ketum as an opium substitute when opium 
itself was unavailable or unaffordable at that time (Burkill, 1935). In 1897, Ridley 
reported that the leaves and bark of Mitragyna speciosa were used as the treatment 
for the opium addiction and in 1907 this statement was repeated by Hooper. Again in 
the same year, Holmes had referred to the leaves as an opium substitute. In 1907, 
Wray explained how ketum was possibly smoked, chewed or drunk to experience the 
opium-like effects in any means of administration (Wray, 1907a).  
Ketum leaves are used for their complex, dose-dependent pharmacological 
effects (Prozialeck et al., 2012). Briefly, mild stimulant effects is experienced at low 
to moderate doses (1-5g) which enable workers to stave off fatigue (Jansen & Prast, 
1988; Suwanlert, 1975). In addition to that, it has been reported that unpleasant sense 
of anxiety and internal agitation are the effects at low dose (Prozialeck et al., 2012). 
Meanwhile at moderate to high doses (5-15g) it’s been reported to have opioid-like 
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effects. Ketum has been used for the pain management, opioid withdrawal symptoms 
and treatment for diarrhea at these doses (Jansen & Prast, 1988; Suwanlert, 1975). 
Finally at very high doses (>15g) ketum is reported to be quite sedative and induces 
stupor and mimicking effects (Grewal, 1932).  
 
2.2.5 Report on Human Usage of Mitragyna speciosa 
Several researchers have conducted studies on ketum usage patterns and 
social behavior (Ahmad & Aziz, 2012; Assanangkornchai et al., 2007). A study done 
on self-proclaimed ketum users has reported that ketum is cheap, easily accessible 
herbal drug with no life threatening adverse effects despite of its long term usage 
(Vicknasingam et al., 2010). Although mild side effects such as dehydration, loss of 
weight and constipation, excessive tearing, discomfort and jerky movement of limbs 
upon cessation has been reported but there were still no serious adverse events were 
recorded. Adding to that, a study on side effects of ketum also reported that long-
term ketum usage made the users to addict towards it (Ahmad & Aziz, 2012). 
Besides that, number of advertisements on its sale on the internet showed that ketum 
is also highly on demand in the internet (Schmidt et al., 2011; Boyer, 2007; Babu et 
al., 2008) Due to the rise of ketum usage among the youth, the law enforcement were 
taken the steps to documenting its usage, side effects and abuse potential before the 
ketum addiction spread worldwide (Ahmad & Aziz, 2012).     
Even though there is no record of death due to ketum consumption; still 
chronic and high dosage can lead to serious adverse reactions in very rare occasion 
(McWhirter & Morris, 2010; Sheleg & Collins, 2011; Nelsen et al., 2010). However 
there are few fatal cases reported due to consuming adulterated ketum products 
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(Kroonstad et al., 2011). Reports reveal that ketum purchased from online traders 
contain a powdered form of ketum and the µ-receptor agonist (O-
desmethyltramadol). This upon consumption has lead to several unintentional 
fatalities due to the present of O-desmethyltramadol and ketum.  
Despite the ban, the ancient practice of consuming ketum as a decoction drink 
still occur among the villagers of northern states of Malaysia. The users are preferred 
the ketum drinks compared to other controlled drugs because of its low cost and easy 
accessibility as it sold in small packets on the streets (Vicknasingam et al., 2010). 
Therefore, large consumption of ketum among its users is due to its easy accessibility 
and the affordability when compared with heroin. Hence, ketum should undergo a 
scientific evaluation to be proven suitable, either directly or as a supplement in 
addiction therapy although, it possess many medicinal values (Vicknasingam et al., 
2010). 
 
2.3 Phytochemistry and pharmacological studies of Mitragyna speciosa 
In 1907, M. speciosa leaves were sent to the University of Edinburgh where, 
14 years later, Wray (1907b) expressed that an active principle would be soon 
isolated and its usefulness to medicine assessed; E.J. Field (1921) isolated an 
alkaloid from the ketum leaves and named it as mitragynine (Jansen & Prast, 1988). 
The first formal pharmacological investigations on mitragynine were carried out at 
the University of Cambridge where Grewel (1932a) performed a series of 
experiments on animal tissues and found mitragynine to be a central nervous system 
stimulant rather than depressant (Jansen & Prast, 1988).  
Since the 1960s, over 25 alkaloids have been isolated and chemically 
characterized from M. speciosa leaves. The main indole alkaloids present in the 
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young leaves of M. speciosa are mitragynine and its analogues, speciogynine, 
paynantheine and speciociliatine. Chemical structures of mitragynine and its major 
analogues are shown Figure 2.2. In addition, a new alkaloid 7-hydroxymitragynine 
was also isolated as a minor constituent (Hassan et al., 2013; Shellard et al., 1978). 
These compounds are commonly found in the young leaves of the plant, which 
possesses a higher alkaloid content of MG as compared to the mature ones. From 
ethyl acetate extracts of young leaves of M. speciosa, MG, speciogynine, 
speciociliatine, paynantheine, 7-hydroxymitragynine, mitragynaline, 
corynantheidaline, corynantheidine and isocorynoxeine were found along with the 
minor constituents, 9-methoxymitralactonine and mitralactonine (Takayama, 2004). 
In the methanolic extract of the mature leaves the above mentioned main alkaloids 
were also found along with the minor constituents such as mitragynaline, pinoresinol, 
mitralactonal, mitrasulgynine and 3,4,5,6-tetradehydromitragynine (Takayama et al., 
1998). The content of the alkaloids varies with geographical locations and also the 
season of the plant (Shellard, 1974). For instance, MG content of Thai M. speciosa 
was 66% of the total alkaloids while the Malaysian species contained only 12% of 
the total alkaloids (Takayama, 2004). The alkaloid profile of M. speciosa is 
summarized in Table 2.1.  
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Figure 2.2: Chemical structures of mitragynine and its major analogues present in the 
leaves of M. speciosa 
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Corynantheidine 
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Table 2.1: Alkaloid profile of Mitragyna speciosa Korth. Percentage refers to the 
estimated content in the alkaloids extracts  
Alkaloid Percentage 
(%) 
Pharmacology 
Mitragynine  
66 
Activity on μ, Ȣ, and κ receptors. 
Analgesic, antitussive, antidiarrheal, 
adrenergic, antimalarial. 
Paynantheine  
9 
Inhibits twitch contraction in 
naloxone insensitive manner. Inhibits 
muscarine receptors on ileal smooth 
muscle. 
Speciogynine  
7 
Inhibits twitch contraction in 
naloxone insensitive manner. Inhibits 
muscarine receptors on ileal smooth 
muscle. 
7-Hydroxymitrgynine  
 
2 
13- and 46-fold higher potency than 
morphine and mitragynine, 
respectively. Potency and quick-
acting characteristics may be caused 
by introduction of –OH group on C7 
position. Induces clinically 
significant antinociceptive responses 
in a dose-dependent manner. 
Analgesic, antitussive, antidiarrheal.   
Speciociliatine  
1 
C3 stereoisomer of mitragynine. 
Inhibits twitch contraction in 
naloxone insensitive manner. May 
inhibit acetylcholine release from 
presynaptic nerve through means 
other than opioid receptor 
stimulation.  
Mitrapylline  
1 
Vasodilator, antihypertensive, muscle 
relaxer, diuretic, antiamnesic, 
immunostimulant, anti-leukemic. 
Isomitrapylline  
1 
Immunostimulant, anti-leukemic 
Speciophylline 1 Anti-leukemic 
Rhynchophylline  
1 
Vasodilator, antihypertensive, 
calcium channel blocker, 
antiaggregant, anti-inflammatory, 
antipyretic, anti-arrhythmic, 
antithelmintic. 
Isorhynchopylline 1 Immunostimulant 
Ajmalicine  
1 
Cerebrocirculant, antiaggregant, anti-
adrenergic, sedative, anticonvulsant, 
smooth muscle relaxer. 
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Corynantheidine 1 Opioid agonist 
Corynoxine A 1 Calcium channel blocker, anti-
locomotive 
Corynoxine B 1 Anti-locomotive 
Mitrafoline 1  
Isomitrafoline 1  
Oxindale A 1  
Oxindole B 1  
Speciofoline 1 Analgesic, antitussive 
Isospeciofoline 1  
Ciliaphylline 1 Analgesic, antitussive 
Mitraciliatine 1  
Mitragynaline 1  
Mitragynalinic acid 1  
Corynantheidalinic  
Acid 
 
1 
 
(Prozialeck et al., 2012; Hassan et al., 2013) 
 
2.3.1 Mitragynine  
Mitragynine is the major indole-alkaloid that is isolated from M. speciosa 
leaves. The structure of mitragynine was fully determined in 1965 by Zacharias et al. 
(1965) through X-ray Crystallography. Takayama et al. (1995) conducted the first 
synthesis of mitragynine followed by Ma et al. (2009) who reported the alternative 
way of mitragynine synthesis. The chemical structure of mitragynine is similar to 
yohimbine (Adkins et al, 2011). This is illustrated in figure 2.2. Chemically, 
mitragynine is called 9-methoxy-corynantheidine. 
Mitragynine is a white amorphous powder. It is a lipophilic alkaloid, as 
indicated by the log P value of 1.73 (Ramanathan et al., 2015). Mitragynine has low 
solubility in aqueous and basic media, inversely to an acidic environment, but is acid 
labile. It is soluble in alcohol, chloroform and acetic acid. Mitragynine is unstable in 
simulated gastric fluid with 20% degradation, but stable in simulated intestinal fluid 
(Ramanathan et al., 2015). Therefore pharmacological response of MG varied 
19 
 
extensively due to its low aqueous solubility, hydrophobicity, acid degradable nature 
and high variability of drug release in simulated biological fluids.  
 Mitragynine shows a high affinity towards µ-opioid receptors (Yamamoto et 
al., 1999). In addition, in vitro studies reported that intense opioid agonistic 
properties were seen with its oxidative derivative, mitragynine pseudoindoxyl. 
Pharmacological studies have demonstrated that antinociceptive effect of 
mitragynine is due to its action which targets µ- and δ-opioid receptors (Matsumoto 
et al., 1996a; Tohda et al., 1997). In comparison to morphine MG exhibits higher 
affinity towards the δ- and ĸ-opioid receptors. The opioid agonist activity could be 
attributed to its Nb lone electron pair and methoxy group at the C9 position 
(Takayama, 2004; Hidayat et al., 2010). Besides that, at cell level, mitragynine block 
the neuronal Ca
2+
 channels which leads to the inhibition of neurotransmitter 
discharge from the nerve endings at the vas deferens (Matsumoto et al., 2005b). 
Along these lines this Ca
2+
 channel-blocking impact of mitragynine goes about as a 
key component for pain relieving and other physiological activities of mitragynine. 
Ingestion of herbal products or extracts along with MG could cause herb-drug 
interactions this is majorly due to the same metabolic pathway that MG and herbal 
drugs utilize. MG was repoted to inhibit cytochrome P450 enzyme activities (Hanapi 
et al., 2013).   
Mitragynine also has anti-inflammatory properties. PGE2 is one of the 
strongest inflammatory mediators which are catalyse by the cyclo-oxygenase 
isoforms, COX-1 and COX-2. In macrophage cells the activity of COX-2 mRNA and 
protein expression were inhibit by MG which stops the PGE2 formation. Although, 
MG has no effect on COX-1 mRNA and protein expression at lower dose; it may 
inhibit them at higher concentration (Utar et al., 2011).  
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Many studies on pharmacological activities of ketum and its major alkaloid 
MG have been conducted in animal models. The reports from different analgesic 
studies on rats and mice suggested that MG antinociceptive activity were extensively 
varied according to the doses (5-400mg/kg) administrated to the animal models 
(Sabetghadam et al., 2010; Matsumoto et al., 1996b). Despite the different in MG 
content in the ketum extracts and variation across species, low oral bioavailability 
and its low aqueos solubility may be the reason behind the large dosage variation in 
analgesic studies (Ramanathan & Mansor, 2014; Parthasarathy et al., 2010). 
A research conducted by Shaik Mossadeq et al. (2009) proved that extracts of 
M. speciosa show positive inhibitory effects towards carrageenan induced paw 
oedema and was also prevent the growth of granuloma tissue by increasing the 
development of macrophages, fibroblasts, vascularized and reddened mass tissue. In 
summary, reports suggested that M. speciosa has anti-inflammatory properties; this 
can be associated with an enhanced immunity via pro-inflammatory mediator release 
and stimulation of tissue repair and healing processes.  
As for neurological effects, Idayu et al. (2011) suggested antidepressant 
effects of MG in mice. According to the study, she performed two different tests and 
established corticosterone concentration in mice was decrease by use of MG. The 
two test performed were forced swim test and tail suspension test on mice. 
Several toxicity reports on MG suggested that the level of toxicity in animal 
model is low. A current study in rats was reported to be lethal at dose of 200 mg/kg 
of M. speciosa extract (Azizi et al., 2010), whereas there were no signs of toxicity in 
dogs treated with a high dose of M. speciosa extract (920 mg/kg) (Macko et al., 
1972). The methanolic and alkaloid extracts of M. speciosa were screened in an acute 
toxicity test, the LD50 values in mice were 4.90 g/kg and 173.20 mg/kg respectively 
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(Reanmongkol et al., 2007). Standardized extracts of M. speciosa (methanol) were 
administered orally at three doses of 100, 500 and 1000 mg/kg, the rats did not show 
any behavioral changes and also their eating habits were unaffected. At 1000 mg/kg 
dose elevated levels of creatinine was present indicating nephrotoxicity. 
 
2.4 Pharmacokinetic issues of natural products 
2.4.1 Oral bioavailability 
The most convenient route of drug administration is through oral dosing but 
due to certain chemical properties of herbal concoction or synthetic drugs prevent the 
use of oral dosing. This is a major setback to all the leading pharmacological 
companies in testing newly derived compounds due to the poor oral bioavailability 
(Prentis et al., 1988; Venkatesh & Lipper, 2000). Thus, this phenomenon causes 
significant costs for pharmaceutical companies (Arlington, 2000).  
The process where the amount and the rate of an unaltered drug reached the 
targeted site within the body is known as bioavailability (Amidon et al., 1995). 
Briefly, an oral bioavailability is a process where the drug transports from the 
gastrointestinal tract through the apical membrane of the epithelial cells (eg: 
enterocytes) to the systemic circulation. In the process of reaching the systemic 
circulation, the drug passed through the enterocytes cells into the pre-hepatic blood 
vessels which collect in the portal vein before entering the liver. Oral bioavailability 
of a drug is a three steps process which are the portion of dose absorbed (fa); the 
portion of drug escaped the gut wall metabolism (fg); and the portion of drug escaped 
from hepatic metabolism (fh) (Fig 2.3) (Dahan et al., 2011). In summary, oral 
bioavailability of a drug is explained in the following general equation (Eq. 2.1):  
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Equation 2.1: F = fa x fg x fh   
 
fg and fh can be further defined in terms of the extraction ratios of the intestinal-based 
metabolism (Eg) and hepatic-based metabolism (Eh) as follows (Eq. 2.2). 
 
Equation 2.2: F = fa (1- Eg)(1-Eh)  
 
 
 
Figure 2.3: Oral drug absorption process from the gastrointestinal tract (GIT). 
Schematic depicting the three major processes (fa, fg, and fh) affecting absorption of 
drug from the site of administration to the systemic circulation passage, that is oral 
bioavailability. fa, fg, and fh can be estimated from the general relationship provided 
in Equation 2.3. 
(Source: Picture adopted from Ehrhardt & Kim, 2008) 
 
Equation 2.3: fa,fg or fh = (MassIN − MassOUT) / MassIN 
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Absorption of a drug is relying on number of physiological, physiochemical, 
and dosage form factors. Adding to that, physiochemical properties of the drug and 
the bio-physiochemical properties of the gastrointestinal membrane play the key role 
in the drug absorption (Ho et al., 1977). Biopharmaceutical Classification System 
(BCS) was developed after the detail studies and researches on primary factors which 
were influencing the drug absorption. Under BCS, absorption of a drug is classified 
based on its solubility and membrane permeability characteristics (Amidon et al., 
1995) as shown in Table 2.2.       
 
Table 2.2: Biopharmaceutical Classification System 
Class I 
High Solubility 
High Permeability 
Class II 
Low Solubility 
High Permeability 
 
Class III 
High Solubility 
Low Permeability 
Class IV 
Low Solubility 
Low Permeability 
 
2.4.2 Solubility and gastrointestinal stability 
In the drug discovery process, the lead candidates must have desirable 
physicochemical properties in order to have a better chance of success in the 
development. Solubility, pKa (ionization constant) and lipophilicity are the most 
fundamental physicochemical properties of a drug candidate. Poor oral 
bioavailability and less desirable physicochemical properties are the main reasons 
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behind the failure of numerous pharmacologically active metabolites to become 
pharmaceutical drugs. Thus, solubility and permeability characteristics of a drug 
included in the drug discovery programs (Delaney, 2005; Huuskonen, 2001).  
BCS recommends determining the solubility of drug substances under 
physiological pH conditions. The experiments should be carried out at 37 ± 1 °C in 
aqueous media with a pH range of 1.2 to 7.5 and to obtain accurate solubility data, 
the pH solubility profile of the compound should be determined based on its pKa. 
Prior to permeability studies, it is essential to determine the stability of the drug in 
gastric and intestinal fluids. These results will assist in obtaining accurate 
permeability values. This is because while conducting in situ or in vivo permeability 
studies there is a possibility for degradation of the drug in the gastric or intestinal 
fluids prior to absorption which will lead to erroneous permeability determination  
(USFDA, 2014). 
 
2.4.3 Intestinal permeability 
Besides the pharmacological activity of new chemical substance, sequential 
profiling which reveal their solubility, absorption, distribution, metabolism, 
elimination and toxicity are the key factors which lead to the selection and 
optimization of the compound (Trapani et al., 2004; Li, 2004). Solubility and the 
permeability characteristics of a drug are the important attributes of the drug 
bioavailability. Although the solubility of a drug can be improve with the aid of the 
proper formulation, the chances of enhance the intestinal membrane permeability are 
very likely restricted. Therefore, determination of the intestinal permeability is one 
essential requirement for assessing the oral bioavailability of a new drug candidate at 
the early drug discovery stage (Volpe, 2008). 
